Nucleus RadioPharma discussed pivotal moments from 2024 and forecast the RLT advancements they expect to see in 2025.

Hear recaps of how 2024 advancements in precision diagnostics and radioligand therapies have shaped treatment accessibility, advancements in biotech buying, expedited drug delivery, and the recent breaking news of CMS’ CY25 rule to enhance payment for specialized diagnostic radiopharmaceuticals.